Matthias Birkhoff is Vice-President Business Development at Aptar Pharma. In this role, he is responsible for Aptar Pharma’s Eye Care programme and co-ordinates research and development activities, microbiological assessment and commercial strategies. Before joining Aptar Pharma in 1998, Mr Birkhoff began his career in pharmaceutical sales at a major multinational pharma company. Prior to his roles in business development and marketing at Aptar Pharma, he was responsible for sales in the Asia Pacific region. He studied medicine at the University of Dusseldorf (Germany) and holds a nursing degree.
Alexandra Ritter and Matthias Birkhoff discuss the importance of the regulatory support the company offers to its customers for preservative-free ophthalmic platforms in the face of increasingly stringent regulatory requirements from both the EU EMA and US FDA, and describe new opportunities and growing demand for a wider range of multidose preservative-free ophthalmic drug-device combinations, including for indications such as dry-eye and glaucoma.